The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Reassuring Data on Cancer Risk with Contemporary RA Drugs

Reassuring Data on Cancer Risk with Contemporary RA Drugs

September 20, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—A large Swedish study1 provides reassuring data on the risk of cancer in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF) inhibitors or with tocilizumab, abatacept or rituximab.

You Might Also Like
  • Does Methotrexate Increase Skin Cancer Risk?
  • TNF Inhibitors May Not Be Linked to Cancer Risk in Kids
  • TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates
Also By This Author
  • Bone Turnover Markers Show Link to Iliac Histomorphometry in Older Women

Overall, the risk of malignant neoplasms did not differ between patients treated with a first anti-TNF drug; a second anti-TNF drug; tocilizumab, abatacept, rituximab; or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), with the possible exception of an increased risk of squamous cell skin cancer in patients treated with abatacept, the study team reported online September 18 in JAMA Internal Medicine.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Considering the widespread and increasing use of biological disease-modifying anti-rheumatic drugs (bDMARDs) to treat chronic inflammatory conditions, and the concern that immunomodulation may alter cancer risk and progression, the limited available data on use of these therapies as used in clinical practice and cancer risks are a concern,” Dr. Hjalmar Wadstrom from the Karolinska Institutet in Stockholm and the Anti-Rheumatic Therapy in Sweden (ARTIS) study group, note in their paper.

Using registry data, they identified cohorts of RA patients starting treatment with tocilizumab, abatacept, or rituximab; those using a TNF inhibitor as a first-ever or second-ever bDMARD; a biologics-naive cohort treated with csDMARDs; and a general population comparator cohort.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The dataset totaled 15,129 initiations of a TNF inhibitor as the first or second bDMARD, 7,405 initiations of other bDMARDs, and 46,610 csDMARD users, as well as 107,491 adults in the general population.

Across the cohorts, the mean age varied from 58 to 64, and the proportion of women varied from 71% to 80%.

“In this study, to our knowledge one of the largest observational studies on the risk of malignant neoplasms in RA patients treated with bDMARDs to date, we found that the overall risk of developing cancer among patients with RA initiating treatment with TNF inhibitors or non-TNF inhibitors, as used in clinical practice, did not differ from that of patients with bDMARD-naive RA,” Dr. Wadstrom and colleagues report.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“We found no increased risk of malignant neoplasms overall, with 95% CIs (confidence intervals) excluding clinically meaningfully increased risks. In addition, we found no increase in risk among patients starting TNF inhibitor as second bDMARD,” they say.

There were no “signals” of increased risks for any specific cancer types, with the exception of abatacept, with the data suggesting an increased risk of squamous cell skin cancer (adjusted hazard ratio, 2.15), although the researchers caution that this observation needs to be replicated.

A limitation of the study is that follow-up time and statistical power are “inherently limited to less than 10 years,” given the relatively recent introduction of non-TNF inhibitor therapy in RA.

Despite this, they say it can be concluded from this study that “short-to medium-term use of tocilizumab, abatacept, rituximab, or anti-TNF drugs seems to be safe with regard to risks of incident cancer.”

Reference

  1. Wadström H, Frisell T, Askling J, et al. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. JAMA Intern Med. 2017 Sept 18. [Epub ahead of print]

 

 

 

Pages: 1 2 | Multi-Page

Filed Under: Drug Updates, Rheumatoid Arthritis Tagged With: Cancer, cancer risk, Karolinska Institutet in Stockholm, Rheumatoid Arthritis (RA), Swedish study, tumor necrosis factor (TNF) inhibitors

You Might Also Like:
  • Does Methotrexate Increase Skin Cancer Risk?
  • TNF Inhibitors May Not Be Linked to Cancer Risk in Kids
  • TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates
  • Small Increased Risk for CIN & Cervical CA with TNF Inhibitors

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)